Quick Answer
TuHURA Biosciences, Inc./NV reported Net Income of -$30.05 million for fiscal year 2025.
TuHURA Biosciences, Inc./NV — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$30.05M -261.2% |
-$8.32M +43.2% |
-$14.65M +35.4% |
-$22.66M +40.8% |
-$38.30M -319.7% |
-$9.13M -13.4% |
| Diluted EPS | -$0.63 +47.9% |
-$1.21 +51.0% |
-$2.47 | — | — | — |
| Total Assets | $27.35M +341.0% |
$6.20M +55.9% |
$3.98M -75.1% |
$15.95M +17.8% |
$13.54M +361.0% |
$2.94M -27.2% |
| Cash and Equivalents | $3.62M -26.3% |
$4.91M +219.8% |
$1.53M -87.0% |
$11.78M +11.8% |
$10.54M +340.5% |
$2.39M -35.7% |
| Stockholders Equity | $20.93M +457.2% |
$3.76M +414.0% |
$731.0K -93.8% |
$11.79M +11.5% |
$10.58M +3923.2% |
$263.0K -86.6% |
| R&D Expense | $20.53M +671.0% |
$2.66M -71.4% |
$9.31M -38.6% |
$15.17M +28.4% |
$11.81M +225.5% |
$3.63M -0.9% |
| Shares Outstanding | 59.34M +41.2% |
42.03M +245.4% |
12.17M | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2012 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$7.10M | -27.3% | +25.4% |
| Diluted EPS | September 30, 2025 | -$0.14 | +74.1% | +33.3% |
| Total Assets | September 30, 2025 | $25.70M | +520.7% | -25.8% |
| Cash and Equivalents | September 30, 2025 | $2.70M | -10.7% | -68.3% |
| Stockholders Equity | September 30, 2025 | $16.78M | +706.3% | -13.7% |
| R&D Expense | September 30, 2025 | $4.97M | +68.6% | +0.8% |
| Operating Income | December 31, 2012 | -$3.2K | +70.2% | +70.2% |
| Shares Outstanding | September 30, 2025 | 51.25M | — | +2.7% |
- TuHURA Biosciences, Inc./NV reported Net Income of -$30.05 million for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed a decrease of -38.6% in Net Income compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported Diluted EPS of $0.63 per share (loss) for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed an increase of +47.9% in Diluted EPS compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported Total Assets of $27.35 million for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed an increase of +37.0% in Total Assets compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported Cash and Equivalents of $3.62 million for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed a decrease of -71.4% in Cash and Equivalents compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported Stockholders Equity of $20.93 million for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed an increase of +43.4% in Stockholders Equity compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported R&D Expense of $20.53 million for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed an increase of +54.0% in R&D Expense compared to the prior fiscal year.
- TuHURA Biosciences, Inc./NV reported Shares Outstanding of 59.34 million shares for fiscal year 2025.
- TuHURA Biosciences, Inc./NV showed an increase of +387.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: